newsfilter
← Latest News
GlobeNewswire·

Corbus Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

Phase 1/2 dose expansion data for Nectin-4 targeting ADC CRB-701 to be presented at ESMO 2025Initiated 7-day MAD portion of Phase 1 study for obesity drug CRB-913All three clinical programs (CRB-701, CRB-913, CRB-601) on